Food & Drug Law Blog

Digital Media

Truck with Pills

How You Source Drugs and Criminal Liability

Written by Michael A. Walsh on September 12, 2014

In June 2014, the office manager at a hematology and oncology center pleaded[MJH1]  guilty to purchasing and selling unapproved and improperly labeled chemotherapy drugs and the center paid $2M to reimburse Centers for Medicare and Medicaid Services (CMS) for submitting “false claims.”  The “crime” was purchasing the drugs from a Canadian supplier whose drug products Read More…

soft drink

News Break: New York to Remain the “Big” Apple

Written by Michael A. Walsh on July 2, 2014

Big Apple or Crabapple? The underlying issue In the Matter of New York Statewide Coalition of Hispanic Chambers of Commerce, et al v. New York City Department of Health and Mental Hygiene, et al., was straightforward: If a consumer knows his actions are potentially harmful to his health, but chooses to act against his best Read More…


The Preemption Pendulum: The Supreme Court Punts Stengel v. Medtronic

Written by Michael A. Walsh on June 24, 2014

Drug and Medical Device Manufacturers Beware; State-law Parallel Claims Threaten As failure-to-warn claims, the decades-old staple of medical products liability, are relegated to the trash bin of tort jurisprudence, a new and more potent approach—parallel claims—has emerged. What are parallel claims, where did they come from, why did they emerge, and when will the Supreme Court Read More…


POM v Coca-Cola: The FDA, the Lanham Act and Regulation through Litigation

Written by Michael A. Walsh on June 13, 2014

The Supreme Court decided POM Wonderful LLC v the Coca Cola Company  on June 12, 2014.  If you listened to the oral argument you would have assumed Coke’s chance of success was proportional to the .3% of pomegranate juice in its pomegranate beverage.  POM purported to assert a “classic false advertising case” that the de Read More…


FDA, Social Media & Promotional Labeling: Frees Speech or Freeze Speech

Written by Michael A. Walsh on May 16, 2014

The Food and Drug Administration (FDA) docket recently closed on the “Draft Guidance for Industry on Fulfilling Regulatory Requirements for Post Marketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics” (Social Media Guidance), and the comments are significant. (See our prior post here). Collectively, the comments submitted to the FDA Read More…